Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegenerative Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SRRM2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SRRM2 Domain-Specific Recombinant Protein (N-terminal / SR-rich domains) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View SRRM2 Products |
| Gene Delivery | SRRM2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View SRRM2 Products |
| Benchmark Ab | Anti-SRRM2 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP assays. |
View SRRM2 Products |
| Validator | SRRM2 siRNA Set For knockdown verification and functional loss-of-function assays. |
View SRRM2 Products |
| Related Target A | SF3B1 Core spliceosome component; highly synergistic in splicing-modulator oncology pipelines. |
View SF3B1 Products |
| Related Target B | SRSF2 Splicing factor mutated in myeloid neoplasms; key node in aberrant splicing networks. |
View SRSF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intrinsically Disordered Regions (IDRs) and Large Size (~300 kDa) Expression | Domain-specific rational design (truncated functional domains) expressed in E. coli or Insect cells with sequence-verified purity >95% |
| Splicing Complex Co-Immunoprecipitation (Co-IP) Background | High-specificity recombinant benchmark antibodies ensuring clean pulldowns without IgG heavy/light chain interference |
| Lack of Controls | Sequence-verified clinical biosimilar and target-specific recombinant validation antibodies included |
| False Positives in Splicing Assays | Validated siRNA pools included for target-specific knockdown verification in splicing reporter assays |
Live SRRM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RNA splicing-targeted therapeutics is intensifying, with major players shifting focus from traditional global spliceosome inhibitors to selective splicing modulators and target-specific degraders (PROTACs). As first-generation splicing inhibitors (such as those targeting SF3B1) navigate clinical trials, the next wave of R&D is targeting critical scaffolding proteins like SRRM2.
SRRM2 acts as a giant structural hub in the catalytic step II spliceosome (C complex). Aberrant SRRM2 expression or phosphorylation is heavily implicated in triple-negative breast cancer (TNBC), hematological malignancies, and neurodegenerative pathologies such as Parkinson's and Alzheimer's diseases. By disrupting the protein-protein or protein-RNA interactions of SRRM2, researchers aim to selectively induce intron retention or exon skipping in oncogenic transcripts, offering a novel avenue for precision oncology and neurology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors / PPI Disruptors | H3 Biomedicine, Skyhawk Therapeutics | Myelodysplastic Syndromes (MDS), Solid Tumors | Recombinant SRRM2 functional domains for binding affinity assays (HTS / SPR) |
| PROTAC / Splicing Factor Degraders | Arvinas, C4 Therapeutics | Refractory Myeloid Leukemia, Advanced Solid Tumors | Lentivirus-driven stable cell lines for target degradation kinetic assays (Western/AlphaLISA) |
| Antisense Oligonucleotides (ASOs) | Ionis Pharmaceuticals, Biogen | Neurodegenerative Diseases (PD, AD) | SRRM2 siRNA and cDNA clones for target modulation and splicing rescue assays |